Department of Vascular and Endovascular Surgery, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Department of Radiology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
J Endovasc Ther. 2024 Oct;31(5):964-974. doi: 10.1177/15266028231158971. Epub 2023 Mar 8.
The purpose of the study was to evaluate the midterm and long-term outcomes of patients who underwent thoracic endovascular aortic repair (TEVAR) procedure to treat an uncomplicated acute and subacute type B aortic dissection (uATBAD) with high risk for subsequent aortic complications compared with the group of patients who received a conservative treatment protocol during the same period.
Between 2008 and 2019, 35 patients who had TEVAR due to uATBAD and those with conservative procedure (n=18) were included in a retrospective analysis and follow-up study. The primary endpoints were false lumen thrombosis/perfusion, true lumen diameter, and aortic dilatation. The aortic-related mortality, reintervention, and long-term survival were the secondary endpoints.
In the study period, 53 patients (22 females) with a mean age of 61.1±13 years were included. No 30-day and in-hospital mortality was recorded. Permanent neurological deficits occurred in 2 patients (5.7%). In the TEVAR group (n=35) and in a median follow-up period of 34 months, a significant reduction of maximum aortic and false lumen diameter as well as a significant increase of true lumen diameter were detected (p<0.001 each). Complete false lumen thrombosis increased from 6% preoperatively to 60% at follow-up. The median difference in aortic, false lumen, and true lumen diameter was -5 mm (interquartile range [IQR]=-28 to 8 mm), -11 mm (IQR=-53 to 10 mm), and 7 mm (IQR=-13 to 17 mm), respectively. In 3 patients (8.6%), a reintervention was needed. Two patients (1 aortic-related) died during follow-up. The estimated survival according to Kaplan-Meyer analysis was 94.1% after 3 years and 87.5% after 5 years. Similar to the TEVAR group, no 30-day or in-hospital mortality was recorded in the conservative group. During follow-up, 2 patients died and 5 patients underwent conversion-TEVAR (28%). In a median follow-up period of 26 months (range=150), a significant increase of maximum aortic diameter (p=0.006) and a tendency to augmentation of the false lumen (p=0.06) were noted. No significant reduction of the true lumen was seen.
Thoracic endovascular aortic repair in patients at high risk of subsequent aortic complications in uncomplicated acute and subacute type B aortic dissection is safe and is associated with favorable midterm outcomes regarding aortic remodeling.
In a retrospective, single center analysis of prospectively collected data with follow-up, we compared 35 patients with high-risk features who recieved TEVAR in acute and sub-acute uncomplicated type B aortic dissection to a control-group (n=18). The TEVAR group showed a significant positive remoduling (reduction of max. aortic and false lumen diameter and increase of true lumen diameter (p<0.001 each)) during follow-up with an estimated survival of 94.1% after 3 years and 87.5% after 5 years.
本研究旨在评估与同期接受保守治疗方案的患者相比,接受胸主动脉腔内修复术(TEVAR)治疗高危非复杂性急性和亚急性 B 型主动脉夹层(uATBAD)患者的中期和长期结果。
2008 年至 2019 年,35 例因 uATBAD 而行 TEVAR 的患者(n=35)和接受保守治疗的患者(n=18)被纳入回顾性分析和随访研究。主要终点为假腔血栓形成/灌注、真腔直径和主动脉扩张。主动脉相关死亡率、再次干预和长期生存率为次要终点。
研究期间,纳入了 53 例(22 例女性)平均年龄为 61.1±13 岁的患者。无 30 天和住院期间的死亡率。2 例(5.7%)出现永久性神经功能缺损。在 TEVAR 组(n=35)和中位随访 34 个月时,均检测到最大主动脉和假腔直径显著减小,真腔直径显著增大(均 P<0.001)。完全假腔血栓形成从术前的 6%增加到随访时的 60%。主动脉、假腔和真腔直径的中位数差值分别为-5 毫米(四分位距[IQR]=-28 至 8 毫米)、-11 毫米(IQR=-53 至 10 毫米)和 7 毫米(IQR=-13 至 17 毫米)。3 例(8.6%)需要再次干预。2 例患者(1 例主动脉相关)在随访期间死亡。根据 Kaplan-Meier 分析,3 年后生存率为 94.1%,5 年后生存率为 87.5%。与 TEVAR 组相似,保守治疗组无 30 天或住院期间的死亡率。随访期间,2 例患者死亡,5 例患者接受转换 TEVAR(28%)。在中位随访 26 个月(范围=150)时,最大主动脉直径显著增加(P=0.006),假腔增大趋势(P=0.06)。真腔直径未见明显减小。
对于高危非复杂性急性和亚急性 B 型主动脉夹层患者,胸主动脉腔内修复术是安全的,并与中期主动脉重塑的有利结果相关。
在一项前瞻性收集数据的回顾性、单中心分析中,我们比较了 35 例具有高危特征的患者,他们在急性和亚急性非复杂性 B 型主动脉夹层中接受了 TEVAR,并与对照组(n=18)进行了比较。TEVAR 组在随访期间表现出显著的正重塑(最大主动脉和假腔直径减小,真腔直径增加(均 P<0.001)),3 年后估计生存率为 94.1%,5 年后为 87.5%。